$5.79 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter
Brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to post sales of $5.79 million for the current quarter, according to Zacks. Four analysts have issued estimates for ADMA Biologics’ earnings. The lowest sales estimate is $5.00 million and the highest is $6.30 million. ADMA Biologics posted sales of $12.00 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 51.8%. The company is scheduled to issue its next earnings report on Monday, March 4th.
According to Zacks, analysts expect that ADMA Biologics will report full-year sales of $19.60 million for the current financial year, with estimates ranging from $18.00 million to $21.00 million. For the next fiscal year, analysts expect that the firm will post sales of $50.66 million, with estimates ranging from $27.00 million to $111.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The company had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $5.39 million.
NASDAQ ADMA traded down $0.48 during trading hours on Friday, reaching $5.26. 177,456 shares of the company were exchanged, compared to its average volume of 226,392. ADMA Biologics has a 1 year low of $2.10 and a 1 year high of $6.96. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65. The company has a market capitalization of $266.97 million, a PE ratio of -2.75 and a beta of 2.28.
Large investors have recently modified their holdings of the business. AMP Capital Investors Ltd bought a new position in ADMA Biologics during the second quarter worth about $109,000. Renaissance Technologies LLC bought a new position in ADMA Biologics during the second quarter worth about $132,000. Schwab Charles Investment Management Inc. bought a new position in ADMA Biologics during the second quarter worth about $160,000. Spark Investment Management LLC boosted its position in ADMA Biologics by 68.7% during the second quarter. Spark Investment Management LLC now owns 37,460 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 15,260 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in ADMA Biologics during the first quarter worth about $182,000. Hedge funds and other institutional investors own 55.07% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Recommended Story: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.